Chronic hepatitis B virus screening prior to rituximab: A quality improvement project. (Record no. 2592)

MARC details
000 -LEADER
fixed length control field 03379nam a22003257a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 170823s20122012 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 0732-183X
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 28147148
245 ## - TITLE STATEMENT
Title Chronic hepatitis B virus screening prior to rituximab: A quality improvement project.
251 ## - Source
Source Journal of Clinical Oncology. 30(34_suppl):199, 2012 Dec
252 ## - Abbreviated Source
Abbreviated source J Clin Oncol. 30(34_suppl):199, 2012 Dec
253 ## - Journal Name
Journal name Journal of clinical oncology : official journal of the American Society of Clinical Oncology
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2012
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2013
266 ## - Date added to catalog
Date added to catalog 2017-08-23
501 ## - WITH NOTE
Local holdings Available online from MWHC library: 1999 - present, Available in print through MWHC library: 1999 - 2008
520 ## - SUMMARY, ETC.
Abstract 199 Background: Patients' with chronic hepatitis B (HBV) are at risk for HBV reactivation and liver failure with initiation of rituximab therapy. HBV testing prior to rituximab for patients with non-Hodgkin lymphoma was a quality measure for the American Society of Clinical Oncology's Quality Oncology Practice Initiative in Spring 2011.
520 ## - SUMMARY, ETC.
Abstract CONCLUSIONS: The HBV screening rate improved after QI intervention although statistically insignificant in multivariate analysis. We identified characteristics associated with low screening rates which will guide future QI strategy.
520 ## - SUMMARY, ETC.
Abstract METHODS: We assessed the pre-intervention HBV screening rate retrospectively from July 2009 to July 2011. Patient demographics, pathology, regimen, and prescriber were abstracted from the electronic medical record. Screening was complete if serum HBVsurface antigen was checked within 3 months prior to rituximab. A quality improvement (QI) intervention was initiated and all prescribers were informed of the screening rate in December 2011. Post-intervention, patients who received rituximab from January 2012 to July 2012 were identified and the same data was abstracted. HBV screening rates across categories pre and post-intervention were analyzed with Fisher's exact test and multivariate logistic regression analysis.
520 ## - SUMMARY, ETC.
Abstract RESULTS: A total of 146 patients (127 pre-intervention, 19 post-intervention) were included. There were more male and rituximab combination therapy in the post-intervention group. The HBV screening rate increased from 59% to 90% (p<0.01) after our QI project. In univariate analysis, factors associated with HBV screening were (1) prior treatment with rituximab (no: 72% vs. yes: 46%, p<0.01), (2) treatment regimen (rituximab alone: 68% vs. combination: 42%, <0.01) and (3) prescriber (full time: 69% vs. part time: 7%, <0.01) In multivariate logistic regression analysis, the odds of HBV screening increased 4.8 times in the post-intervention group compared to pre-intervention group although this was statistically not significant (p=0.07). Prior rituximab (Odds Ratio (OR) 0.4, 95%CI 0.2-0.9), combination regimen (OR 3.2, 95% CI 1.5-7.2), and full-time prescriber (OR 25.1, 95% CI 2.8-255.4) were statistically significant for HBV screening.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element IN PROCESS -- NOT YET INDEXED
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution Washington Cancer Institute
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Jang, Sekwon
790 ## - Authors
All authors Jang S
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="https://dx.doi.org/10.1200/jco.2012.30.34_suppl.199">https://dx.doi.org/10.1200/jco.2012.30.34_suppl.199</a>
Public note https://dx.doi.org/10.1200/jco.2012.30.34_suppl.199
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 08/23/2017   28147148 28147148 08/23/2017 08/23/2017 Journal Article

Powered by Koha